Experienced in Congenital Generalized Fibromatosis

Dr. Francis W. Nugent

Hematology Oncology | Hematology | Oncology
Pratt Medical Group Inc
800 Washigton St, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Congenital Generalized Fibromatosis
Pratt Medical Group Inc
800 Washigton St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Francis Nugent is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Nugent is rated as an Experienced provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Fibrolamellar Carcinoma, Familial Colorectal Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Gastrostomy. Dr. Nugent is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Tufts Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

PRATT MEDICAL GROUP INC
800 Washigton St, Boston, MA 02111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer
A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: February 07, 2024
Intervention Type: Drug
Study Drug: Anamorelin Hydrochloride
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Multi-Center Phase III Study of Individualized Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as a Bridge to Transplant in Hepatocellular Carcinoma.
A Randomized Multi-Center Phase III Study of Individualized Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as a Bridge to Transplant in Hepatocellular Carcinoma.
Enrollment Status: Terminated
Publish Date: August 28, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drug: Doxorubin
Study Phase: Phase 3
A Randomized Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) With DEBDOX Beads as a Bridge to Transplant in Hepatocellular Carcinoma.
A Randomized Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) With DEBDOX Beads as a Bridge to Transplant in Hepatocellular Carcinoma.
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drug: Doxorubin
Study Phase: Phase 2
View 4 Less Clinical Trials

7 Total Publications

Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) as a Bridge to Transplant in Unresectable Hepatocellular Carcinoma.
Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) as a Bridge to Transplant in Unresectable Hepatocellular Carcinoma.
Journal: Annals of surgical oncology
Published: May 27, 2021
Similar Doctors
Advanced in Congenital Generalized Fibromatosis
Dr. Andrew J. Wagner
Hematology Oncology | Oncology | Hematology
Advanced in Congenital Generalized Fibromatosis
Dr. Andrew J. Wagner
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.4 miles away)
617-632-3586
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Wagner is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Wagner is rated as a Distinguished provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Rhabdomyosarcoma Embryonal, Alveolar Soft Part Sarcoma, and Adult Soft Tissue Sarcoma. Dr. Wagner is currently accepting new patients.

Advanced in Congenital Generalized Fibromatosis
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology
Advanced in Congenital Generalized Fibromatosis
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.9 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Cote is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cote is rated as an Elite provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Adult Soft Tissue Sarcoma, Chordoma, Epithelioid Sarcoma, Synovial Sarcoma, and Tissue Biopsy.

Advanced in Congenital Generalized Fibromatosis
Dr. Edwin Choy
Hematology Oncology | Oncology
Advanced in Congenital Generalized Fibromatosis
Dr. Edwin Choy
Hematology Oncology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (0.9 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Choy is rated as an Elite provider by MediFind in the treatment of Congenital Generalized Fibromatosis. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Synovial Sarcoma. Dr. Choy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nugent's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile